Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

To be considered for this study, your doctors first need to check a sample of your cancer tissue (either an old sample or a new one) to see if it has the specific 'NECTIN4 amplification'. This is a key requirement. You also need to have cancer that can be measured, meaning doctors can track its size and changes. Your general health should be good enough to participate, with a life expectancy of at least 12 weeks, and you should be able to perform your usual daily activities without too much difficulty.

For those with HR+/HER2- negative breast cancer, you should have already tried at least one, but no more than three, other treatments for your advanced cancer that were not hormone-based. If you have triple-negative breast cancer, you also need to have received at least one, but no more than three, previous treatments for your advanced cancer. This includes some cases where the cancer is 'ER-low positive'.

There are also some reasons why you wouldn't be able to join. For instance, if you've already had a similar type of drug called an 'antibody drug conjugate' that contained a specific chemical called MMAE. You also can't be allergic to any ingredients in the study drug. Other reasons might include certain eye conditions, active cancer that has spread to your brain or spinal cord, uncontrolled diabetes or high blood pressure, or serious lung problems. Your doctors will review all these points carefully to see if this study is right for you.

If you decide to take part in this study, you will receive the study drug, zelenectide pevedotin, as part of your treatment. The study is 'open-label', which means both you and your doctors will know you are receiving this specific drug. You will have regular visits to the clinic for check-ups, blood tests, and scans to see how the treatment is working and to monitor your health. The duration of your participation will depend on how you respond to the treatment and the study plan, but you will be monitored closely throughout. Specific details about the frequency of visits and tests will be discussed thoroughly by the study staff.